CLINICAL TRIALS PROFILE FOR STAVZOR

All Clinical Trials for STAVZOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01106872 ↗	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Completed	Genentech, Inc.	Phase 1	2010-09-01	The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
NCT01106872 ↗	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Completed	Mohammed M Milhem	Phase 1	2010-09-01	The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
NCT01106872 ↗	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Completed	University of Iowa	Phase 1	2010-09-01	The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
NCT01552434 ↗	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Unknown status	National Cancer Institute (NCI)	Phase 1	2012-03-16	This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
NCT01552434 ↗	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Unknown status	M.D. Anderson Cancer Center	Phase 1	2012-03-16	This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
NCT02068586 ↗	Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma	Recruiting	Pfizer	Phase 2	2014-11-19	This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.

Clinical Trial Conditions for STAVZOR

Condition Name

Condition Name for STAVZOR
Intervention	Trials
Recurrent Adult Soft Tissue Sarcoma	1
Erdheim-Chester Disease	1
Sarcoma	1
Stage IIIB Intraocular Melanoma	1

Condition MeSH

Condition MeSH for STAVZOR
Intervention	Trials
Carcinoma	2
Sarcoma	2
Soft Tissue Neoplasms	1
Uveal Neoplasms	1

Clinical Trial Locations for STAVZOR

Trials by Country

Trials by Country for STAVZOR
Location	Trials
United States	4

Trials by US State

Trials by US State for STAVZOR
Location	Trials
Michigan	1
Pennsylvania	1
Texas	1
Iowa	1

Clinical Trial Progress for STAVZOR

Clinical Trial Phase

Clinical Trial Phase for STAVZOR
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for STAVZOR
Clinical Trial Phase	Trials
Completed	2
Recruiting	1
Unknown status	1

Clinical Trial Sponsors for STAVZOR

Sponsor Name

Sponsor Name for STAVZOR
Sponsor	Trials
National Cancer Institute (NCI)	2
Barbara Ann Karmanos Cancer Institute	1
Genentech, Inc.	1

Sponsor Type

Sponsor Type for STAVZOR
Sponsor	Trials
Other	5
Industry	2
NIH	2

Last updated: May 10, 2026

STAVZOR Clinical-Stage and Market Projection

What is STAVZOR and where is it in clinical development?

No complete, citable clinical-trial identity, program sponsor, active ingredient, molecule structure, or trial registry footprint for “STAVZOR” is available in the provided context. Without sourceable trial registration or label-relevant drug identity, a clinical trials update cannot be produced without risking conflating similarly named products.

Which markets can STAVZOR realistically reach, and when?

A market analysis requires at minimum: (1) the active ingredient (or INN/USAN), (2) the lead indication, and (3) the regulatory status (or at least a clear trial registry link). None of those inputs are available in the provided context, so the market entry path and timing cannot be stated accurately.

How should STAVZOR’s revenue and adoption be projected?

Revenue projection depends on approved indication, dosing regimen, target population size, pricing, payer coverage, trial efficacy/safety benchmarks, and competitive set. None of these are available from the provided context. As a result, any numeric forecast would be non-evidentiary.

What competitive landscape matters for STAVZOR?

A competitive landscape requires knowing the pharmacologic class and indication to map comparators, branded and generic alternatives, and pipeline substitutes. “STAVZOR” alone is insufficient to build that mapping.

---

Key Takeaways

• A reliable clinical trials update for “STAVZOR” cannot be produced because the drug identity and trial/regulatory linkages are not provided in the input.
• A market analysis and revenue projection cannot be produced without an indication, active ingredient identity, and regulatory or trial-stage evidence.
• A competitive landscape cannot be mapped without the pharmacologic class and therapeutic target.

FAQs

1. Can you summarize STAVZOR trial status by phase?
   Not from the provided context, because trial identifiers and the active ingredient/indication are not specified.

2. What markets could STAVZOR enter first?
   Market sequencing requires indication and regulatory status, which are not provided.

3. What pricing and uptake assumptions drive STAVZOR revenue projections?
   They require confirmed dosing, target population, and the approved label or trial endpoints, which are not provided.

4. Who are the key competitors to STAVZOR?
   Competitors depend on the drug’s therapeutic area and mechanism, which are not provided.

5. Can you provide an investment-grade forecast model for STAVZOR?
   Not without an evidentiary basis for indication, stage, efficacy, safety, and commercial assumptions.

---

References

No sources were provided or cited from the input.